| Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study H Gacaferi, GS Collaborative, COVIDSurg Collaborative Anaesthesia 76 (6), 2021 | 549* | 2021 |
| Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ A Gronchi, AB Miah, AP Dei Tos, N Abecassis, J Bajpai, S Bauer, ... Annals of Oncology 32 (11), 1348-1365, 2021 | 519 | 2021 |
| Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label … A Gronchi, S Ferrari, V Quagliuolo, JM Broto, AL Pousa, G Grignani, ... The Lancet Oncology 18 (6), 812-822, 2017 | 459 | 2017 |
| A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study G Grignani, E Palmerini, P Dileo, SD Asaftei, L D’ambrosio, Y Pignochino, ... Annals of Oncology 23 (2), 508-516, 2012 | 376 | 2012 |
| Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial WD Tap, H Gelderblom, E Palmerini, J Desai, S Bauer, JY Blay, T Alcindor, ... The Lancet 394 (10197), 478-487, 2019 | 336 | 2019 |
| Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial G Grignani, E Palmerini, V Ferraresi, L D'Ambrosio, R Bertulli, SD Asaftei, ... The lancet oncology 16 (1), 98-107, 2015 | 333 | 2015 |
| Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, JY Blay, N Abecassis, J Bajpai, S Bauer, R Biagini, S Bielack, ... Annals of oncology 33 (1), 20-33, 2022 | 272 | 2022 |
| Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma S Ferrari, E Palmerini Current opinion in oncology 19 (4), 341-346, 2007 | 266 | 2007 |
| Elective cancer surgery in COVID-19–free surgical pathways during the SARS-CoV-2 pandemic: an international, multicenter, comparative cohort study JC Glasbey, D Nepogodiev, JFF Simoes, O Omar, E Li, ML Venn, PGDME, ... Journal of Clinical Oncology 39 (1), 66-78, 2021 | 265 | 2021 |
| Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study J Glasbey, A Ademuyiwa, A Adisa, E AlAmeer, AP Arnaud, F Ayasra, ... The Lancet Oncology 22 (11), 1507-1517, 2021 | 245 | 2021 |
| Advanced chondrosarcomas: role of chemotherapy and survival A Italiano, O Mir, A Cioffi, E Palmerini, S Piperno-Neumann, C Perrin, ... Annals of oncology 24 (11), 2916-2922, 2013 | 237 | 2013 |
| Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial … S Ferrari, P Ruggieri, G Cefalo, A Tamburini, R Capanna, F Fagioli, ... Journal of clinical oncology 30 (17), 2112-2118, 2012 | 234 | 2012 |
| High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic … G Bacci, M Rocca, MC Salone, A Balladelli, S Ferrari, E Palmerini, C Forni, ... Journal of surgical oncology 98 (6), 415-420, 2008 | 226 | 2008 |
| Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up SJ Strauss, AM Frezza, N Abecassis, J Bajpai, S Bauer, R Biagini, ... Annals of Oncology 32 (12), 1520-1536, 2021 | 199 | 2021 |
| Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study S Chawla, JY Blay, P Rutkowski, A Le Cesne, P Reichardt, H Gelderblom, ... The Lancet Oncology 20 (12), 1719-1729, 2019 | 191 | 2019 |
| Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution E Palmerini, EL Staals, M Alberghini, L Zanella, C Ferrari, MS Benassi, ... Cancer 115 (13), 2988-2998, 2009 | 191 | 2009 |
| Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups A Gronchi, E Palmerini, V Quagliuolo, J Martin Broto, A Lopez Pousa, ... Journal of Clinical Oncology 38 (19), 2178-2186, 2020 | 185 | 2020 |
| Phase II study on lapatinib in advanced EGFR-positive chordoma S Stacchiotti, E Tamborini, SL Vullo, F Bozzi, A Messina, C Morosi, ... Annals of oncology 24 (7), 1931-1936, 2013 | 150 | 2013 |
| Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution M Cesari, F Bertoni, P Bacchini, M Mercuri, E Palmerini, S Ferrari Tumori Journal 93 (5), 423-427, 2007 | 150 | 2007 |
| Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): for how long? E Palmerini, NS Chawla, S Ferrari, M Sudan, P Picci, E Marchesi, ... European Journal of Cancer 76, 118-124, 2017 | 145 | 2017 |
Piero PicciFounder and Past President I.S.G. Italian Sarcoma Group. Former Director of Exp. Onc. Ist. RIZZOLI在 italiansarcomagroup.org 的电子邮件经过验证
